Expression and prognostic significance of pepsinogen C in gastric carcinoma

被引:29
作者
Fernández, R
Vizoso, F
Rodríguez, JC
Merino, AM
González, LO
Quintela, I
Andicoechea, A
Truan, N
Díez, MC
机构
[1] Hosp Jove, Serv Cirugia Gen & Anat Patol, Gijon, Spain
[2] Hosp Cabuenes, Serv Anat Patol, Gijon, Spain
关键词
gastric cancer; prognosis; pepsinogen C; pepsinogen A;
D O I
10.1007/s10434-000-0508-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: in this study we evaluated the expression and clinical significance of pepsinogen C, an aspartic proteinase involved in the digestion of proteins in the stomach, in patients with gastric cancer. Methods: Pepsinogen C expression was examined by immunohistochemical methods in a series of 95 gastric carcinomas. The prognostic value of pepsinogen C was retrospectively evaluated by multivariate analysis taking into account conventional prognostic parameters. Follow-up period of patients was 21.4 months. Results: A total of 25 (26.3%) gastric carcinomas stained positively for pepsinogen C. The percentage of pepsinogen C-positive tumors was higher in well-differentiated (50%) than in moderately differentiated (19.5%) and poorly differentiated (21.9%) tumors (P < .05). Similarly, significant differences in pepsinogen C immunostaining were found between node-negative and node-positive tumors (47.1% vs. 14.7%; P < .001). in addition, statistical analysis revealed that pepsinogen C expression was associated with clinical outcome in gastric cancer patients. Low pepsinogen C levels predicted short overall survival periods in the overall group of patients with gastric cancer (P < .001), and in 71 patients with resectable carcinomas (P < .005). Multivariate analysis according to Cox's model indicated that pepsinogen C immunostaining was an independent predictor of outcome for both overall and resectable gastric cancer patients (P < .05, for both). Conclusions: The expression of pepsinogen C in gastric cancer may represent a useful biological marker able to identify subgroups of patients with different clinical outcomes.
引用
收藏
页码:508 / 514
页数:7
相关论文
共 49 条
[11]  
Gottesman M., 1990, SEMIN CANCER BIOL, V1, P97
[12]   Sensitivity and specificity of mass screening for gastric cancer using the measurement of serum pepsinogens [J].
Hattori, Y ;
Tashiro, H ;
Kawamoto, T ;
Kodama, Y .
JAPANESE JOURNAL OF CANCER RESEARCH, 1995, 86 (12) :1210-1215
[13]   TUMOR-ASSOCIATED PROTEOLYSIS AND PROGNOSIS - NEW FUNCTIONAL RISK-FACTORS IN GASTRIC-CANCER DEFINED BY THE UROKINASE-TYPE PLASMINOGEN-ACTIVATOR SYSTEM [J].
HEISS, MM ;
BABIC, R ;
ALLGAYER, H ;
GRUETZNER, KU ;
JAUCH, KW ;
LOEHRS, U ;
SCHILDBERG, FW .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :2084-2093
[14]  
HERMANEK P, 1992, UICC TNM CLASSIFICAT
[15]   ENZYME-LINKED IMMUNOSORBENT ASSAYS FOR SERUM PEPSINOGEN-I AND PEPSINOGEN-II USING MONOCLONAL-ANTIBODIES - WITH DATA ON PEPTIC-ULCER AND GASTRIC-CANCER [J].
HUANG, SC ;
MIKI, K ;
FURIHATA, C ;
ICHINOSE, M ;
SHIMIZU, A ;
OKA, H .
CLINICA CHIMICA ACTA, 1988, 175 (01) :37-50
[16]   METHYLATION AND EXPRESSION OF HUMAN PEPSINOGEN GENES IN NORMAL-TISSUES AND THEIR ALTERATION IN STOMACH-CANCER [J].
ICHINOSE, M ;
MIKI, K ;
WONG, RNS ;
TATEMATSU, M ;
FURIHATA, C ;
KONISHI, T ;
MATSUSHIMA, M ;
TANJI, M ;
SANO, J ;
KUROKAWA, K ;
TAKAHASHI, T ;
KAGEYAMA, T ;
TANG, JJN ;
TAKAHASHI, K .
JAPANESE JOURNAL OF CANCER RESEARCH, 1991, 82 (06) :686-692
[17]   RADIOIMMUNOASSAY OF SERUM GROUP-I AND GROUP-II PEPSINOGENS IN NORMAL CONTROLS AND PATIENTS WITH VARIOUS DISORDERS [J].
ICHINOSE, M ;
MIKI, K ;
FURIHATA, C ;
KAGEYAMA, T ;
HAYASHI, R ;
NIWA, H ;
OKA, H ;
MATSUSHIMA, T ;
TAKAHASHI, K .
CLINICA CHIMICA ACTA, 1982, 126 (02) :183-191
[18]  
Ito H, 1996, VIRCHOWS ARCH, V427, P487
[19]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[20]  
KIKUCHI S, 1994, CANCER, V73, P111